The OrganOx metra device was recently featured in use for a pioneering clinical trial (VITTAL) by the liver transplant team at the Queen Elizabeth II Hospital, Birmingham, UK. This pioneering study team is placing livers declined for transplant by all UK liver transplant centres on the OrganOx metra device, assessing their quality, and if deemed viable, transplanting them. Watch the documentary on BBC iPlayer (only available within the UK) HERE.
OrganOx is pleased to share the recent interview with co-founder Professor Constantin Coussios in The Economist. The metra® device normothermic liver perfusion technology was discussed, along with exciting plans for the future. Read more HERE
OrganOx, a leader in the field of organ preservation, has signed a 5 year agreement with Dismeval to distribute the OrganOx metra in Spain.
" We are delighted to have signed up Dismeval s.l to ensure the OrganOx metra is adopted in Spain. In terms of organ donation rates Spain leads the rest of the world, very much helped by the opt-out policy which has been in place since 1979. We have been impressed with Dismeval's track record over many years in driving other innovative surgical products into the Spanish market. With Dismeval as our partner in Spain we look forward to seeing the positive impact of our technology benefiting all involved in liver transplantation. " said Craig Marshall, CEO of OrganOx Limited.
"We recognise the potential of the OrganOx metra to further improve the utilisation of deceased donor livers in Spain. We anticipate first sales into leading Spanish liver transplant hospitals centres in Q4 of 2017" said Salvador Forés, General Manager of Dismeval s.l.
OrganOx, a leader in the field of organ preservation, has signed a 5 year agreement with Avidal Group GmbH to distribute the OrganOx metra in Germany, Austria and Switzerland.
As part of the agreement Avidal is committed to securing marketing approval for the CE marked metra in each of these 3 countries.
“ We are delighted to have signed up the Avidal Group to ensure the OrganOx metra is adopted in these 3 key European countries. We have been impressed with Avidal’s track record over many years in driving other innovative surgical and interventional products into these markets. With Avidal as our partner in Germany, Austria and Switzerland we look forward to establishing a significant presence in these countries in the coming years” said Craig Marshall, CEO of OrganOx Limited.
“We recognise the potential of the OrganOx metra to dramatically improve the utilisation of deceased donor livers, we see a huge opportunity for this product in the countries we serve. The marketing approval process in Germany is particularly complex, but it a process we at Avidal Group understand very well, and in the case of the OrganOx metra we actually began this process, in good faith, almost 12 months ago. We anticipate first sales into German liver transplant hospitals centres in Q4 of 2017” said Torsten Heilmann, CEO of Avidal Group GmbH.
OrganOx is pleased to announce support of a local and very relevant charity, the Oxford Transplant Foundation. The mission of this charity is to further the science and practice of transplantation, and to provide support for education and training in transplantation, over and above that provided by the University of Oxford and National Health Service.
Learn more about the foundation HERE.